Generality-oriented development of novel methods for the synthesis of enantioenriched sulfondiimines using data science
Active Project Grant Awarded Last action
- Award ID
- F32GM157872
- Recipient
-
University Of Utah UEI LL8GLEVH6MG3
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $520,840
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date 52% complete
- Place of performance
- Salt Lake City, UT 84112, USA
Award details come from USAspending.gov.
Description
- Abstract
- Sulfur is an important heteroatom in pharmaceuticals, with 30% of the top-grossing small- molecule drugs in 2022 containing sulfur. Highly oxidized sulfur functional groups, such as sulfonamides, are particularly common. Sulfondiimines are a type of high oxidation state sulfur compound that can be chiral, which is an important property in drug molecules. However, synthesis of sulfondiimines, especially with high selectivity for one enantiomer, can be challenging and exhibit poor safety profiles. IT is clear that the development of improved methods for sulfondiimine synthesis would be beneficial. One approach to method development is using data science, which can expedite the optimization process by allowing for in silico screening. Data science models have the potential to give insight into mechanistic details of reactions when applied in tandem with computational chemistry tools and careful data generation. A challenge within this method development is to identify general conditions that work for many compounds of a general synthetic goal. One approach to develop a generalizable reaction is by optimizing conditions around several compounds rather than a single model substrate. Thus, the primary aim of this proposal is to develop generalizable novel synthetic methods for sulfondiimines using data science. This goal will be achieved by applying a generality-oriented, data science-driven reaction development approach to two specific aims: (1) a desymmetrization of sulfondiimines and (2) selective addition to fluoro-Λ6-sulfanenitriles. The separate synthetic strategies could allow for access to a broader range of sulfondiimines, as each may exhibit different reactivity profiles for various compounds. These methods will be showcased through broad substrate scopes featuring syntheses of sulfondiimine analogues for known sulfonamide-containing cancer drugs. A long- term application of this proposal is the synthesis of a library of sulfondiimine analogues of known drug targets for analysis as potential therapeutics.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1,248 | |
| Amendment | $75,052 | |
| Amendment | $75,052 | |
| Amendment | $1,224 | |
| Amendment | $1,224 | |
| Amendment | $73,408 | |
| Amendment | $0 | |
| Amendment | $73,408 | |
| Amendment | $0 | |
| Amendment | $73,408 | |
| Amendment | $73,408 | |
| Amendment | $0 | |
| Amendment | $73,408 | |
| Original award | $0 |
Show all 14
Quick answers
Who received award F32GM157872?
F32GM157872 was awarded to University Of Utah by National Institute of General Medical Sciences (National Institutes of Health) on June 10, 2025.
How much is award F32GM157872 worth?
$520,840 has been obligated on F32GM157872.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award